Related references
Note: Only part of the references are listed.Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
David L. Kendler et al.
ADVANCES IN THERAPY (2022)
Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM)
Soren Moller et al.
OSTEOPOROSIS INTERNATIONAL (2022)
Osteoporosis in Europe: a compendium of country-specific reports
Carl Willers et al.
ARCHIVES OF OSTEOPOROSIS (2022)
Evaluating Patients for Secondary Causes of Osteoporosis
E. Michael Lewiecki
CURRENT OSTEOPOROSIS REPORTS (2022)
Drug therapy for osteoporosis in older adults
Ian R Reid et al.
LANCET (2022)
UK clinical guideline for the prevention and treatment of osteoporosis
Celia L. Gregson et al.
ARCHIVES OF OSTEOPOROSIS (2022)
Management of patients at very high risk of osteoporotic fractures through sequential treatments
Elizabeth M. Curtis et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2022)
Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Elena Tsourdi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services
W. F. Lems et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review
A. M. Burden et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Closing the Osteoporosis Care Gap
Kristina E. Akesson et al.
CURRENT OSTEOPOROSIS REPORTS (2021)
Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada
Jonathan D. Adachi et al.
BMC MUSCULOSKELETAL DISORDERS (2021)
The treatment gap: The missed opportunities for osteoporosis therapy
Nicholas R. Fuggle et al.
BONE (2021)
Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption
Michelle M. McDonald et al.
CELL (2021)
Approaches to Fracture Risk Assessment and Prevention
Sanford Baim et al.
CURRENT OSTEOPOROSIS REPORTS (2021)
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
Felicia Cosman et al.
CURRENT OSTEOPOROSIS REPORTS (2021)
The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis
N. Li et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Short time horizons for fracture prediction tools: time for a rethink
E. V. McCloskey et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Risk of Subsequent Fractures in Postmenopausal Women After Nontraumatic vs Traumatic Fractures
Carolyn J. Crandall et al.
JAMA INTERNAL MEDICINE (2021)
SCOPE 2021: a new scorecard for osteoporosis in Europe
John A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2021)
Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study
Christian Roux et al.
JBMR PLUS (2021)
Opportunistic diagnosis of osteoporosis, fragile bone strength and vertebral fractures from routine CT scans; a review of approved technology systems and pathways to implementation
Veena Aggarwal et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)
Risk factors for imminent fractures: a substudy of the FRISBEE cohort
L. Iconaru et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2020)
History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture
Emese Toth et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study
C. Condurache et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Interventions to improve osteoporosis care: a systematic review and meta-analysis
J. Martin et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis
T. Merlijn et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Fragility fractures in Europe: burden, management and opportunities
Fredrik Borgstrom et al.
ARCHIVES OF OSTEOPOROSIS (2020)
A broader strategy for osteoporosis interventions
Ian R. Reid
NATURE REVIEWS ENDOCRINOLOGY (2020)
A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network
M. K. Javaid et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review
D. Cornelissen et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Characterization of fracture liaison service non-responders after invitation by home visits and questionnaires
P. van den Berg et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Defining Very High Fracture Risk: IsFRAXFit for Purpose?
Juliet E. Compston et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Determinants of imminent fracture risk in postmenopausal women with osteoporosis
R. L. Barron et al.
OSTEOPOROSIS INTERNATIONAL (2020)
FRAX: re-adjust or re-think
Yasser El Miedany
ARCHIVES OF OSTEOPOROSIS (2020)
Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis
Kosuke Ebina et al.
BONE (2020)
Thoracic Kyphosis on Chest CT Scans Is Associated With Incident Vertebral Fractures in Smokers
Mayke J. van Dort et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
S. Ferrari et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression
C. Beaudoin et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Risk of imminent fracture following a previous fracture in a Swedish database study
J. Banefelt et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Long-Term Effects of Teriparatide Followed by Antiresorptive Therapy on Clinical Outcomes in Patients with Severe Spinal Osteoporosis
Ailsa J. Oswald et al.
CALCIFIED TISSUE INTERNATIONAL (2019)
Two-Thirds of All Fractures Are Not Attributable to Osteoporosis and Advancing Age: Implications for Fracture Prevention
Ha T. Mai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Challenges and opportunities to improve fracture liaison service attendance: fracture registration and patient characteristics and motivations
P. van den Berg et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Primary care physicians' views on osteoporosis management: a qualitative study
Helena Salminen et al.
ARCHIVES OF OSTEOPOROSIS (2019)
The association between prevalent vertebral fractures and bone quality of the distal radius and distal tibia as measured with HR-pQCT in postmenopausal women with a recent non-vertebral fracture at the Fracture Liaison Service
L. Vranken et al.
OSTEOPOROSIS INTERNATIONAL (2019)
The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial
Thomas Merlijn et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials
Ling-Feng Zeng et al.
FRONTIERS IN PHARMACOLOGY (2019)
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Risk of subsequent fracture after prior fracture among older women
A. Balasubramanian et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2019)
Comorbidities and medication use in patients with a recent clinical fracture at the Fracture Liaison Service
L. Vranken et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study
K. H. Rubin et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Long-term treatment strategies for postmenopausal osteoporosis
Felicia Cosman
CURRENT OPINION IN RHEUMATOLOGY (2018)
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
High Imminent Vertebral Fracture Risk in Subjects With COPD With a Prevalent or Incident Vertebral Fracture
Mayke J. van Dort et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS)
Annette L. Adams et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study
David A. Turner et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
Piet Geusens et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial
Lee Shepstone et al.
LANCET (2018)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Ian R. Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Systemic Bone Loss After Fracture
Benjamin Osipov et al.
CLINICAL REVIEWS IN BONE AND MINERAL METABOLISM (2018)
EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures
W. F. Lems et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Imminent risk of fracture after fracture
H. Johansson et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Spinal Loading Patterns From Biomechanical Modeling Explain the High Incidence of Vertebral Fractures in the Thoracolumbar Region
Alexander G. Bruno et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Worldwide Fracture Prediction
Ghada El-Hajj Fuleihan et al.
JOURNAL OF CLINICAL DENSITOMETRY (2017)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of implementation of guidelines on assessment and diagnosis of vertebral fractures in patients older than 50 years with a recent non-vertebral fracture
R. Y. van der Velde et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Predictors of near-term fracture in osteoporotic women aged ae65 years, based on data from the study of osteoporotic fractures
D. Weycker et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Imminent fracture risk
C. Roux et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures
N. C. W. Harvey et al.
OSTEOPOROSIS INTERNATIONAL (2017)
The Phenotype of Patients with a Recent Fracture: A Literature Survey of the Fracture Liaison Service
Lisanne Vranken et al.
CALCIFIED TISSUE INTERNATIONAL (2017)
Barriers to Effective Postmenopausal Osteoporosis Treatment: A Qualitative Study of Patients' and Practitioners' Views
Sophie Alami et al.
PLOS ONE (2016)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Clinician's Guide to Prevention and Treatment of Osteoporosis
F. Cosman et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study
Douglas C. Bauer et al.
JAMA INTERNAL MEDICINE (2014)
The role of the combination of bone and fall related risk factors on short-term subsequent fracture risk and mortality
Kirsten M. B. Huntjens et al.
BMC MUSCULOSKELETAL DISORDERS (2013)
Comparison of different screening tools (FRAX®, OST, ORAL OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study
Katrine Hass Rubin et al.
BONE (2013)
Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
General medical practitioners' knowledge and beliefs about osteoporosis and its investigation and management
Renée Otmar et al.
Archives of Osteoporosis (2012)
Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans
Tony M. Keaveny et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Enhanced prediction of fracture risk combining vertebral fracture status and BMD
E. S. Siris et al.
OSTEOPOROSIS INTERNATIONAL (2007)
From best evidence to best practice: effective implementation of change in patients' care
R Grol et al.
LANCET (2003)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
